China Biologic Products Holdings, Inc. (CBPO) Company Bio
China Biologic Products engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in China. The company is based in Beijing, the China.
CBPO Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for China Biologic Products Holdings Inc. To summarize, we found that China Biologic Products Holdings Inc ranked in the 55th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 65.67% on a DCF basis. In terms of the factors that were most noteworthy in this DCF analysis for CBPO, they are:
The company's debt burden, as measured by earnings divided by interest payments, is 300.33; that's higher than 97.53% of US stocks in the Healthcare sector that have positive free cash flow.
The business' balance sheet suggests that 0% of the company's capital is sourced from debt; this is greater than merely 0% of the free cash flow producing stocks we're observing.
CBPO's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 63.89% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
AMED, SNY, FTLF, LH, and TVTY can be thought of as valuation peers to CBPO, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.